1-3 of 3
Sumimasa Nagai, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Analysis of Drugs for Hematological Malignancy That Were Granted Accelerated Approval and Feasibility of Randomized Phase 3 Clinical Trials for Relapsed and Refractory Hematological Malignancy

Free
Sumimasa Nagai, MD, PhD, Keiya Ozawa, MD PhD
Journal: Blood
Blood (2016) 128 (22): 2387.
https://doi.org/10.1182/blood.V128.22.2387.2387
Published: 2016
Journal Articles

Endpoints of Clinical Trials for Marketing Authorization of Drugs for Hematologic Malignancy in Japan, the US and the EU

Free
Sumimasa Nagai, MD, PhD
Journal: Blood
Blood (2014) 124 (21): 2603.
https://doi.org/10.1182/blood.V124.21.2603.2603
Published: 2014
Journal Articles

The Comparison of Review Processes of Hematological Malignancy Drugs Between the Pmda and the FDA

Free
Sumimasa Nagai, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 4243.
https://doi.org/10.1182/blood.V120.21.4243.4243
Published: 2012